

# 18/C.  
Goiga  
4.903


ATTORNEY'S DOCKET NO: A00752.70001.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregory L. Stahl et al.  
Serial No.: 09/464,303  
Filed: December 15, 1999  
For: METHODS AND PRODUCTS FOR REGULATING LECTIN COMPLEMENT  
PATHWAY ASSOCIATED COMPLEMENT ACTIVATION  
Examiner: Amy DeCloux  
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 4<sup>th</sup> day of April, 2003.

  
Janice A. Vatland

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

APR 14 2003

AMENDMENT

TECH CENTER 1600/2900

Sir:

This amendment is submitted in response to the Office Action mailed from the United States Patent and Trademark Office on October 15, 2002.

In the Claims:

Please amend claim 18 to read as follows:

C  
18. (Thrice Amended) A composition, comprising an isolated-binding peptide that—  
selectively binds to a human MBL epitope, wherein the isolated MBL binding peptide has an  
MBL binding CDR3 region or a functional variant thereof of a monoclonal antibody produced by  
a hybridoma cell line selected from the group consisting of hybridoma cell line<sub>(3F8)</sub> hybridoma  
cell line<sub>(2A9)</sub>, and hybridoma cell line<sub>(hMBL1.2)</sub> deposited under ATCC accession numbers HB-  
12621, HB-12620, and HB-12619 respectively, and wherein the functional variant thereof has an  
MBL binding CDR3 region with a conservative substitution therein.